SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
167
THE MECHANISM OF ALCOHOLIC LIVER DAMAGE
Radjabova Gulchehra Bahodirovna
Bukhara State Medical Institute
The thesis
https://doi.org/10.5281/zenodo.15425951
Abstract:
Liver diseases, especially acute toxic, ischemic and alcoholic liver
damage, remain one of the main causes of liver failure.
The purpose of the
study:
Investigation of the relationship between metabolic and immunological
parameters in patients after correction with allogeneic hepatocytes. Alcoholic
liver damage is one of the leading causes of liver disease in the world and
represents a wide range of pathological changes, including fatty degeneration,
alcoholic hepatitis, fibrosis and cirrhosis of the liver. It occurs as a result of
prolonged and excessive alcohol consumption, which causes various metabolic,
immunological and cellular changes. It is important to understand exactly how
alcohol affects liver tissue in order to develop effective methods of treatment
and prevention of this disease.
Alcohol metabolism in the liver:
Alcohol (ethanol) is metabolized in the
liver through several key enzymatic systems:
Alcohol
Dehydrogenase (ADH): This enzyme first metabolizes ethanol to
acetaldehyde, which is a toxic substance. Acetaldehyde Dehydrogenase (ALDH):
Acetaldehyde, in turn, is converted to acetic acid, which is then used in
metabolism.
With chronic alcohol abuse, acetaldehyde accumulates in liver cells, which
leads to various damages, such as:
Oxidative stress: Acetaldehyde stimulates the formation of reactive oxygen
radicals (ROS), which causes oxidative stress and damage to cell membranes,
mitochondria, and DNA. Violation of the antioxidant system: Chronic alcohol
consumption reduces the activity of antioxidant enzymes, which exacerbates the
damage caused by ROS.
Impaired fat metabolism: One of the early manifestations of alcohol damage
is fatty liver disease, or steatosis. This process is caused by a violation of fat
metabolism.:
Activation of fat synthesis: Ethanol stimulates the synthesis of fatty acids in
the liver, which leads to the accumulation of fat in hepatocytes.
Impaired fatty acid oxidation: Chronic alcohol consumption disrupts the
process of fatty acid oxidation in the mitochondria, which also contributes to the
accumulation of fat in the liver. At first, the accumulation of fat in the liver may
SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
168
be reversible (steatosis), but if alcohol abuse continues, it can lead to more
serious damage.
Inflammation and cytokine activation: Cytokine production: Chronic alcohol
consumption increases inflammation through the activation of macrophages and
micronutrient cells, which leads to the release of inflammatory mediators (e.g.
TNF-α, IL-6, IL-1b). Activation of NF-kB: One of the key mechanisms of
inflammation is the activation of the transcription factor NF-kB, which regulates
the expression of cytokines that stimulate inflammation.
Inflammation in the liver can cause damage to hepatocytes and activate
fibrosis, as well as contribute to the progression of the disease to cirrhosis of the
liver.
Fibrosis and cirrhosis of the liver: Prolonged inflammation in response to
alcohol damage leads to activation of Kupffer cells and stellate liver cells, which
causes the production of collagen and other components of the extracellular
matrix. This process leads to liver fibrosis, the replacement of normal liver
tissue with scar tissue. Over time, fibrosis can progress to cirrhosis, which
significantly impairs liver function and leads to liver failure.
Pathogenesis of alcoholic hepatitis: Alcoholic hepatitis is an inflammatory
liver disease that occurs due to prolonged alcohol consumption. It is
characterized by:
Conclusion: Alcoholic liver damage is a complex and multifactorial process
that includes metabolic disorders, inflammation, cell death, and fibrosis.
Prolonged alcohol consumption leads to the accumulation of fat in the liver,
damage to mitochondria, activation of inflammation and fibrosis of liver tissue,
which can progress to cirrhosis and liver failure. Understanding these
mechanisms is important for developing effective methods for the diagnosis and
treatment of alcoholic liver damage, as well as for preventing its progression.
References:
1. Burnevich E.Z. Hepatic encephalopathy in cirrhosis of the liver [Text]
/E.Z.Burnevich, T.N., M.S.Krasnova // Hepatological. forum. – 2018. – No. 2. –pp.
19-24.
2. Butorova L.I. Medicinal liver lesions [Text]: textbook.- methodical. manual /
L.I.Butorova, A.V.Kalinin, A.F.Loginov. Moscow: Federal State University
"NMHTS named after N.I. Pirogov", 2015. 65 p.
3. Vartanyan F.E. Tuberculosis: problems and scientific research in the countries
of the world [Text] / F.E.Vartanyan, K.P.Shakhovsky // Problems of tuberculosis.
2002. No. 8. pp. 48-49.
4. Vasilenko Yu.K. The effect of pectoinulin and its combination with taurine on
SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
169
detoxifying activity of the liver [Text] / Y.K.Vasilenko [et al.] //Vestn. Russian
University of Friendship of Peoples.- 2012. – No. 1. – pp. 22-26.-Ser. Medicine.
5. Vedennikova A.V. Genetic aspects of alcoholic liver disease. The results of the
study [Text] / A.V.Vedennikova [et al.] // Hepatology today: tez.dokl. tenth
Russian Conference– Moscow, 2005– p.57.
6. Vedrova N.N. Experience of using methadoxyl in the complex treatment of
alcoholic liver damage [Text] / N.N. Vedrova, N.Yu. Gnezdilova // Narcologist.-
2005.-No. 4. - pp. 24-26.
7. Vengerovsky A.I. Methodological guidelines for the study of hepatoprotective
activity of pharmacological substances [Text] / A.I.Vengerovsky, I.V.Markova,
A.S.Saratikov // Guidelines for the experimental (preclinical) study of new
pharmacological substances / edited by V.P.Fisenko. – Moscow, 2000. – pp.228-
231.
8. Vengerovsky A.I. Methodological guidelines for the study of hepatoprotective
activity of pharmacological substances [Text] / A.I.Vengerovsky, I.V.Markova,
A.S.Saratikov // Guidelines for the experimental (preclinical) study of new
pharmacological substances / edited by R.U. Khabriev. Moscow, 2005. pp.683-
691. 285
9. Verokhobina N.V. The place of Dibikor in the treatment of patients with type 2
diabetes mellitus and metabolic syndrome [Text] / N.V.Verokhobina,
A.V.Kuznetsova // Pharmateca. - 2012. – No. 3. – pp.75-7
